Form 4: Lemaitre Vascular Director Acquires Dividend Rights

Lemaitre Vascular Director John A. Roush reported the acquisition of dividend equivalent rights tied to previously granted equity awards.

Summary

• John A. Roush, a Director of Lemaitre Vascular Inc. (LMAT), reported the acquisition of dividend equivalent rights (DERs) on September 4, 2025.
• These DERs accrued on previously granted restricted stock unit (RSU) and performance share unit (PSU) awards.
• The DERs vest proportionately with their underlying RSU and PSU awards.
• A total of 3.2727 dividend equivalent rights were acquired on this date across five separate entries.
• Each dividend equivalent right is the economic equivalent of one share of Lemaitre Vascular's common stock.
• The underlying awards were granted on December 12, 2022, December 8, 2023, and December 6, 2024.

Sentiment

Score: 5

Explanation: This Form 4 reports a routine accrual of dividend equivalent rights as part of an existing equity compensation plan for a director, rather than a discretionary purchase or sale of shares. It reflects ongoing compensation mechanisms and alignment but does not indicate new strategic developments or significant shifts in insider sentiment.

Positives

• The acquisition of dividend equivalent rights indicates the director's continued participation in the company's equity compensation plans, aligning their interests with shareholders.
• The vesting of these rights is tied to the underlying RSU and PSU awards, which typically have performance or time-based conditions, suggesting a long-term commitment.

Negatives

• The reported transactions are for fractional dividend equivalent rights, not direct purchases of common stock, which might not signal a strong new investment conviction.
• The 'price' of these rights is reported as $0, as they are accrued benefits rather than direct share purchases.

Risks

• The value of the dividend equivalent rights is tied to the performance of Lemaitre Vascular's common stock, meaning their ultimate value can fluctuate.
• The vesting of these rights is contingent upon the vesting of the underlying RSU and PSU awards, which may have performance conditions or time-based hurdles that could prevent full realization.

Future Outlook

The dividend equivalent rights will vest proportionately with their underlying restricted stock unit and performance share unit awards, indicating future potential share entitlements upon meeting vesting conditions.

Industry Context

The accrual of dividend equivalent rights on equity awards is a a common practice in executive and director compensation plans across various industries, particularly in companies that pay dividends. It ensures that the holders of unvested equity awards receive the economic benefit of dividends, aligning their interests with common shareholders.

Comparison to Industry Standards

• This Form 4 reports a standard mechanism for compensating directors and executives through equity awards that include dividend equivalent rights.
• Many companies, especially in the medical device sector like Lemaitre Vascular, utilize such plans to attract and retain talent and align management incentives with long-term shareholder value.
• Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual's transaction.

Related Party Transactions

• The reported transactions are part of the director's compensation plan, which is a standard arrangement between the company and its director, not a related party transaction in the context of unusual asset sales or purchases.

Stakeholder Impact

• Shareholders: The accrual of dividend equivalent rights aligns the director's interests with shareholders by providing economic benefits equivalent to dividends on unvested equity.

Next Steps

• The dividend equivalent rights will continue to vest in line with the underlying restricted stock unit and performance share unit awards.

Key Dates

Keywords

LMAT, Lemaitre Vascular, Form 4, insider transaction, dividend equivalent rights, equity awards, restricted stock units, performance share units, director compensation